Trial Profile

Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 02 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Agenmestencel-T (Primary) ; Ganciclovir
Indications Adenocarcinoma; Gastrointestinal cancer
Focus Adverse reactions; First in man; Proof of concept
Acronyms TREAT-ME 1
Sponsors Apceth Biopharma

Most Recent Events

31 May 2019 Status has been changed to completed.
31 May 2019 Results assessing safety and tolerabilty of genetically modified autologous mesenchymal stromal cells published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
02 Jun 2015 Tolerability results (phase 1) presented at the 51st Annual Meeting of the American Society of Clinical Oncology. No safety concerns to prevent progression to phase II testing.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com